Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia Lesley J. Scott Adis Drug Evaluation 21 September 2019 Pages: 493 - 504
Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State Petros GrivasBradley J. MonkMarkus Moehler Review Article 18 September 2019 Pages: 505 - 525
Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial Neal ShoreChristian ZurthKarim Fizazi Original Research Article Open access 30 September 2019 Pages: 527 - 539
Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial Ali A. MokdadHao ZhuAdam C. Yopp Original Research Article 19 August 2019 Pages: 541 - 550
Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia Kyle A. UddSean BujarskiJames R. Berenson Original Research Article 31 August 2019 Pages: 551 - 561
Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma Steven I. ParkCarolina P. LinBlossom Damania Original Research Article 19 August 2019 Pages: 563 - 575
Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX) Heike LiewenNorbert MarkulyFrank Stenner Original Research Article 20 September 2019 Pages: 577 - 590
First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer Sung-Bae KimFunda Meric-BernstamJordan Berlin Original Research Article Open access 09 September 2019 Pages: 591 - 601
Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma Models Ofir MorenoJamie Wood Original Research Article Open access 10 September 2019 Pages: 603 - 611
A Phase I Study of GGTI-2418 (Geranylgeranyl Transferase I Inhibitor) in Patients with Advanced Solid Tumors Thomas B. KarasicE. Gabriela ChioreanPeter J. O’Dwyer Short Communication 01 August 2019 Pages: 613 - 618
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion Silvia La MonicaRoberta MinariRoberta Alfieri Short Communication 09 September 2019 Pages: 619 - 626